MiNK Therapeutics (NASDAQ:INKT) Rating Increased to Hold at Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other research firms have also commented on INKT. Zacks Research raised MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Stock Down 0.4%

Shares of NASDAQ:INKT opened at $11.10 on Friday. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $76.00. The firm’s 50 day moving average price is $12.19 and its 200 day moving average price is $13.84. The stock has a market cap of $52.06 million, a price-to-earnings ratio of -3.66 and a beta of 0.34.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.21. On average, equities analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.